Sophie Bouvet charity rescue begins 13621079267 Sophie Bouvet returns to the old and new

_b> Hepatitis C can cause chronic inflammation, necrosis and fibrosis of the liver, and some patients may develop cirrhosis or even hepatocellular carcinoma. What’s even more frightening is that hepatitis C is extremely contagious and very difficult to treat. Once infected, it is difficult to completely cure. Therefore, India’s sofosbuvir, as a specific drug for the treatment of hepatitis C, has been on the market and is in short supply. & I have never seen any drug as popular as Sofosbuvir. &
The launch of India’s specific drug for hepatitis C, Sofosbuvir, has triggered a rush to buy
India’s sofosbuvir, whose English name is br, is a specific < .. specific drug for hepatitis C. The drug was developed by Gilead and was officially launched in the United States with approval from the U.S. Food and Drug Administration (Food and Drug Administration) on January 1, 2019. This listing shocked the medical community and all hepatitis C patients.
According to clinical trials conducted by relevant scientific research institutions, sofosbuvir has very good effects on patients with any type of hepatitis C: for hepatitis C and subtypes, the drug combines pegylated interferon and ribavirin. The overall sustained virological response rate (R) is as high as % against hepatitis C. The R of this drug combined with ribavirin is %-% against hepatitis C. The R of this drug combined with ribavirin is %-%. Even for patients with hepatitis C and cirrhosis, the effect of sofosbuvir is still shocking.
Such a remarkable effect has brought about a rush for Indian Sophia Buve. Especially after the Indian company obtained the production authorization for Sofosbuvir, the relatively low price attracted patients from all over the world to go there or purchase it through purchasing companies.

The drug is the first to safely and effectively treat certain types of hepatitis C without the need for interferon. Clinical trials have confirmed that against hepatitis C, the drug combined with pegylated interferon and ribavirin has an overall sustained virological response rate (R) of up to %. The R of bavirin is %-% against hepatitis C, and the R of this drug combined with ribavirin is %-%. It is worth mentioning that the clinical trials of sofosbuvir also included some patients with hepatitis C and cirrhosis, and the efficacy was also significant.
1. Clinical Application

Usage and Dosage: One tablet per day, taken on an empty stomach or with food.
() Can be combined with ribavirin or ribavirin + pegylated interferon to treat chronic hepatitis C (). The recommended regimen is as follows: single infection or/- combined infection treatment regimen. Duration of treatment: genotype or type sofosbuvir + pegylated interferon-&+ ribavirin. genotype sofosbuvir + ribavirin Week genotype sofosbuvir + ribavirin weeks.
() Patients with chronic hepatitis C who are unable to use interferon may consider using sofosbuvir combined with ribavirin for weekly treatment.
() Hepatocellular carcinoma patients awaiting liver transplantation should use sofosbuvir combined with ribavirin to treat chronic hepatitis C for weeks or until they receive liver transplantation, whichever occurs first.
() Dosing recommendations cannot be made for patients with severe renal impairment or end-stage renal disease.
Adverse reactions: The most common known adverse reactions (incidence rate equal to or greater than %, all grades) caused by sofosbuvir combined with ribavirin are headache and fatigue. Sofosbuvir combined with pegylated interferon The most common known adverse reactions caused by -& ribavirin include fatigue, headache, nausea, insomnia and anemia.
Drug Interactions: Potent intestinal glycoprotein (-) inducers (such as rifampicin) may alter sofosbuvir drug plasma concentrations. Before use, please read the complete package insert for drug-drug interactions.
Medication for special groups: ()/-Patients with co-infections, the safety and effectiveness of this drug have been confirmed by research () Patients with hepatocellular carcinoma waiting for liver transplantation: The safety and effectiveness of this drug have been confirmed by research.
2. Price Differences
Gilead has proposed a tiered pricing system on a global scale, that is, pricing based on a country's per capita gross national income. The company said prices in the U.S. are U.S. dollars per treatment course, prices in the U.K. are approximately U.S. dollars, and prices in Germany are approximately U.S. dollars.

Gilead agreed to supply this new drug on the Egyptian market on 2020. The price of one course of treatment (week) is approximately US dollars, which is approximately 1% of the US market price. Egypt has the highest incidence of HCV in the world. According to previous media reports, Gilead announced this month that it would sell sofosbuvir tablets in India at a price that is % of the US selling price, that is, US dollars per course of treatment. At present, Gilead has expanded the authorization of new hepatitis C drugs. The authorization will include the inhibitor -, which means it authorizes Gilead's partners in India to produce a mixture of - and br (sofosbuvir) / -, and sell it to individuals around the world. Developing countries account for % of the world's hepatitis C patients. Once the br(sofosbuvir)/- combination is approved, it will be the first purely oral hepatitis C drug for patients of all genotypes. So far, a total of Indian pharmaceutical companies have obtained authorization from Gilead.

3. Prospects for listing in my country
According to the public information on the website of the Food and Drug Administration, at least one drug has been applied for listing in China and has entered the review stage, but it still needs to be redone in China. The third phase clinical trial has completed a series of qualification review, import customs declaration, pharmaceutical factory quotation, bidding and procurement and other procedures.
The Food and Drug Administration did not respond to the feasibility of this approach, but Zhang Lan, an official at the WHO Representative Office in China, was not optimistic about it: &In the past few years, drugs have been successfully introduced using this provision. The quantity is zero. We have done a lot of research and tried AIDS drugs and cancer drugs, but none of them were successful. "The aforementioned anonymous official from the Centers for Disease Control and Prevention also said that Article 4 is limited to difficult and critical diseases: "For example, R is fine. "There is currently no data to prove that hepatitis C is a "difficult and critical disease."